Neurobo Common Stock vs Net Tangible Assets Analysis
NRBO Stock | USD 3.78 0.05 1.34% |
Neurobo Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Neurobo Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurobo Pharmaceuticals is a good investment. Please check the relationship between Neurobo Pharmaceuticals Common Stock and its Net Tangible Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.
Common Stock vs Net Tangible Assets
Common Stock vs Net Tangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurobo Pharmaceuticals Common Stock account and Net Tangible Assets. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Neurobo Pharmaceuticals' Common Stock and Net Tangible Assets is -0.01. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Neurobo Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Neurobo Pharmaceuticals' Common Stock and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Neurobo Pharmaceuticals are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Common Stock i.e., Neurobo Pharmaceuticals' Common Stock and Net Tangible Assets go up and down completely randomly.
Correlation Coefficient | -0.01 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Common Stock
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most indicators from Neurobo Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurobo Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.At this time, Neurobo Pharmaceuticals' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 5th of May 2024, Enterprise Value Multiple is likely to grow to 0.23, while Selling General Administrative is likely to drop 6,392.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 48K | 20K | 3K | 2.9K | Cost Of Revenue | 72K | 28K | 7K | 6.7K |
Neurobo Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Neurobo Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurobo Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.5M | 11.0M | 16.8M | 33.5M | 22.8M | 18.4M | |
Short Long Term Debt Total | 116K | 94K | 71K | 203K | 182.7K | 173.6K | |
Other Current Liab | 1.4M | 1.1M | 1.3M | 11.1M | 5.1M | 2.6M | |
Total Current Liabilities | 2.1M | 3.7M | 2.2M | 11.8M | 6.0M | 6.1M | |
Total Stockholder Equity | 12.3M | 7.2M | 14.6M | 21.8M | 16.7M | 17.5M | |
Net Debt | (13.8M) | (10.0M) | (16.3M) | (33.4M) | (22.2M) | (21.1M) | |
Retained Earnings | (36.9M) | (66.5M) | (81.8M) | (95.8M) | (108.3M) | (102.9M) | |
Accounts Payable | 638K | 2.6M | 830K | 708K | 821K | 1.1M | |
Cash | 13.9M | 10.1M | 16.4M | 33.4M | 22.4M | 17.8M | |
Non Current Assets Total | 350K | 285K | 215K | 2K | 269.0K | 220.2K | |
Cash And Short Term Investments | 13.9M | 10.1M | 16.4M | 33.4M | 22.4M | 17.8M | |
Common Stock Total Equity | 18K | 22K | 16K | 20K | 23K | 17.9K | |
Common Stock Shares Outstanding | 21.8K | 67.6K | 96.4K | 321.7K | 5.1M | 5.3M | |
Liabilities And Stockholders Equity | 14.5M | 11.0M | 16.8M | 33.5M | 22.8M | 18.4M | |
Capital Surpluse | 64.4M | 91.9M | 49.1M | 73.7M | 84.8M | 59.9M | |
Other Current Assets | 42K | 48K | 197K | 168K | 77K | 105.8K | |
Other Stockholder Equity | 34.7M | 73.7M | 96.4M | 117.5M | 124.9M | 69.3M | |
Total Liab | 2.2M | 3.8M | 2.2M | 11.8M | 6.1M | 5.8M | |
Total Current Assets | 14.1M | 10.7M | 16.6M | 33.5M | 22.5M | 18.1M | |
Short Term Debt | 22K | 24K | 26K | 67K | 60.3K | 57.3K | |
Common Stock | 16K | 20K | 27K | 25K | 5K | 4.8K | |
Non Currrent Assets Other | 740K | 350K | 130K | 21.0K | 18.9K | 18.0K | |
Non Current Liabilities Total | 94K | 70K | 45K | 708K | 136K | 129.2K | |
Net Tangible Assets | (13.3M) | 12.3M | 7.2M | 14.6M | 16.8M | 17.6M | |
Net Invested Capital | 12.3M | 7.2M | 14.6M | 21.8M | 16.7M | 16.3M | |
Net Working Capital | 12.0M | 7.0M | 14.4M | 21.7M | 16.6M | 14.5M | |
Capital Stock | 16K | 20K | 27K | 25K | 5K | 4.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.35) | Return On Equity (0.65) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.